Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparinHAINER, James W; SPROGEL, Per; LINDENSTROEM, Ewa et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 3-9, issn 0094-6176, 7 p., SUP1Conference Paper

Effects of Heparin and its 6-O- and 2-O-desulfated derivatives with low anticoagulant activity on proliferation of human neural stem/progenitor cellsMORI, Hideki; KANEMURA, Yonehiro; ONAYA, Junichi et al.Journal of bioscience and bioengineering. 2005, Vol 100, Num 1, pp 54-61, issn 1389-1723, 8 p.Article

Heparin-induced thrombocytopenia and recent advances in its therapyHASSAN, Y; AWAISU, A; AZIZ, N. A et al.Journal of clinical pharmacy and therapeutics (Print). 2007, Vol 32, Num 6, pp 535-544, issn 0269-4727, 10 p.Article

Heparin and low-molecular-weight heparin : Current use of biologicals in thrombosis and haemostasisGRAY, Elaine; MULLOY, Barbara; BARROWCLIFFE, Trevor W et al.Thrombosis and haemostasis. 2008, Vol 99, Num 5, pp 807-818, issn 0340-6245, 12 p.Article

Guidelines on the use and monitoring of heparinBAGLIN, T; BARROWCLIFFE, T. W; COHEN, A et al.British journal of haematology. 2006, Vol 133, Num 1, pp 19-34, issn 0007-1048, 16 p.Article

Long-Term Use of Low-Molecular-Weight Heparin in Hemodialysis Patients : A 7-Year ExperienceBERNIEH, B; BOOBES, Y; AL HAKIM, M. R et al.Blood purification. 2009, Vol 27, Num 3, pp 242-245, issn 0253-5068, 4 p.Article

Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with PolymersSZCZUBIALKA, Krzysztof; KAMINSKI, Kamil; ZASADA, Katarzyna et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 18, pp 2591-2606, issn 1381-6128, 16 p.Article

Low-molecular-weight heparins and angiogenesisNORRBY, Klas.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2006, Vol 114, Num 2, pp 79-102, issn 0903-4641, 24 p.Article

Bridging therapy and oral anticoagulation: current and future prospectsSPYROPOULOS, Alex C.Current opinion in hematology. 2010, Vol 17, Num 5, pp 444-449, issn 1065-6251, 6 p.Article

Heparin-induced thrombocytopenia following hip and knee arthroplastyCRAIK, Johnathan D; COBB, Andrew G.British journal of haematology. 2013, Vol 161, Num 2, pp 255-261, issn 0007-1048, 7 p.Article

The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23°CSTIEF, Thomas W.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 2, pp 209-212, issn 0957-5235, 4 p.Article

Standardisation of Unfractionated and Low-Molecular-Weight HeparinGRAY, Elaine.Handbook of experimental pharmacology. 2012, Vol 207, pp 65-76, issn 0171-2004, 12 p.Article

Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopeniaPAYNE, Sonja M; KOVACS, Michael J.The Annals of pharmacotherapy. 2003, Vol 37, Num 5, pp 655-658, issn 1060-0280, 4 p.Article

Removal of the anticoagulant activities of the low molecular weight heparin fractions and fragments with flavobacterial heparinaseYANG, V. C; BERNSTEIN, H; COONEY, C. L et al.Thrombosis research. 1986, Vol 44, Num 5, pp 599-610, issn 0049-3848Article

Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat modelTERAI, Kazuhiro; SUZUKI, Masanori; SASAMATA, Masao et al.Neurochemical research. 2003, Vol 28, Num 5, pp 779-785, issn 0364-3190, 7 p.Article

Clinical use of unfractionated heparin therapy in children: time for change?NEWALL, Fiona; IGNJATOVIC, Vera; JOHNSTON, Linda et al.British journal of haematology. 2010, Vol 150, Num 6, pp 674-678, issn 0007-1048, 5 p.Article

The effect of taurolidine on experimental thrombus formationKAPTANOGLU, Levent; KUCUK, Hasan Fehmi; COLAK, Elif et al.European journal of pharmacology. 2008, Vol 578, Num 2-3, pp 238-241, issn 0014-2999, 4 p.Article

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibratorJESKE, W; AHMAD AHSAN; JAWED FAREED et al.Thrombosis research. 1993, Vol 70, Num 1, pp 39-50, issn 0049-3848Article

Argatroban dosing in patients with heparin-induced thrombocytopeniaVERME-GIBBONEY, Catherine N; HURSTING, Marcie J.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 970-975, issn 1060-0280, 6 p.Conference Paper

Heparin release from slippery-when-wet guide wires for intravascular usePEERLINGS, Camiel C. L; HANSSEN, Hans H. L; BEVERS, Raymond T. J et al.Journal of biomedical materials research. 2002, Vol 63, Num 6, pp 692-698, issn 0021-9304, 7 p.Article

MINIMAL HEPARIN COFACTOR ACTIVITY IN DISSEMINATED INTRAVASCULAR COAGULATION AND CIRRHOSIS.BRAUNSTEIN KM; EURENIUS K.1976; AMER. J. CLIN. PATHOL.; U.S.A.; DA. 1976; VOL. 66; NO 3; PP. 488-494; BIBL. 21 REF.Article

PREPARATION OF THREE TYPES OF HEPARIN-SEPHAROSE AND THEIR BINDING ACTIVITIES TO THROMBIN AND ANTITHROMBIN IIIFUNAHASHI M; MATSUMOTO I; SENO N et al.1982; ANALYTICAL BIOCHEMISTRY; ISSN 0003-2697; USA; DA. 1982; VOL. 126; NO 2; PP. 414-421; BIBL. 26 REF.Article

Heparin-induced thrombocytopenia : What clinicians need to knowCHONG, Beng H; ISAACS, Arend.Thrombosis and haemostasis. 2009, Vol 101, Num 2, pp 279-283, issn 0340-6245, 5 p.Article

Activation of heparin cofactor II by heparin and dermatan sulfateTOLLEFSEN, D. M.Nouvelle revue française d'hématologie. 1984, Vol 26, Num 4, pp 233-237, issn 0029-4810Article